Arcus Biosciences (RCUS) Tops Q3 EPS by 19c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($0.94), $0.19 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $32 million versus the consensus estimate of $27.57 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Arcus Biosciences (RCUS) PT Raised to $45 at H.C. Wainwright
• First United (FUNC) Tops Q2 EPS by 8c
• Calix, Inc. (CALX) Tops Q2 EPS by 6c, Offers Guidance